Market Overview

UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Linzess Survey

Share:
Related IRWD
Benzinga's Top Initiations
Friday's After-Hours Movers: Akorn, Rosetta Resources And More
Ironwood's (IRWD) CEO Peter Hecht on Q1 2015 Results - Earnings Call Transcript (Seeking Alpha)

Credit Suisse upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Outperform and raised the price target from $15.00 to $24.00.

Credit Suisse analyst Catherine Arnold commented, "CS proprietary market research survey with ~100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs, ~70% who were early Linzess users, and all with brand awareness."

Ironwood Pharmaceuticals closed at $17.68 on Thursday.

Latest Ratings for IRWD

DateFirmActionFromTo
May 2015Leerink SwannMaintainsMarket Perform
May 2015JP MorganMaintainsOverweight
Apr 2015Bank of AmericaInitiates Coverage onBuy

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings

 

Related Articles (IRWD)

Around the Web, We're Loving...

Get Benzinga's Newsletters